Authors
Loading...
Randomized trial reveals enhanced anti-tumor immunity in a modified mouse model by targeting Gli2 in Tregs, suggesting new therapeutic avenues.
Swain et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: